A real-world multicenter study on opportunistic cervical cancer screening in hospital in China: comparison of TruScreen device, cytology, and HPV testing for detecting high-grade cervical lesions
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Cervical cancer (CC) remains a major health challenge worldwide. Early detection methods and screening strategies are important for reducing both incidence and mortality rates. OBJECTIVES: This study evaluates the clinical performance of the real-time optoelectronic device, TruScreen (TS), in detecting high-grade cervical precancers compared to standard methods [high-risk human papillomavirus (hrHPV) testing, cytology, and colposcopy) in a Chinese hospital-based opportunistic screening cohort. In addition, assess the clinical effectiveness of the TS strategies alongside current guidelines and methodologies in cervical cancer screening. METHODS: A multicenter, cross-sectional study was conducted across 64 hospitals between September 2018 and June 2021 in China. Participants (n = 14,982 women aged ≥ 20 years) underwent TS test, hrHPV test, liquid-based cytology (LBC), and colposcopy with biopsy confirmation. Diagnostic performance [sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV)] were calculated using histopathology as the gold standard. Strategies incorporating TS test were compared to WHO-recommended guidelines. RESULTS: For cervical intraepithelial neoplasia grade 2 and servier lesions (CIN2+), TS test demonstrated comparable sensitivity (87.0%; 95% CI: 84.8–88.9%) to hrHPV (91.9%) and higher specificity (57.2% vs. 29.2%) than cytology (53.6%). TS test demonstrated outperformed compared to cytology in CIN3+ (sensitivity: 90.0% vs. 62.7%) and maintained high NPV (97.9%). In women aged ≥ 45 years, TS test showed comparable sensitivity (88.5%) to hrHPV test (87.9%) and higher specificity (60.1%) than hrHPV (27.5%) and cytology (46.9%) in CIN3+. Strategy 3, TS combined hrHPV testing, achieved the lowest missed cancer cases (n = 14) and balanced referral rates (19.65%), produced the best results among the methods compared. CONCLUSION: The straightforward operation and non-invasive detection of TS test demonstrate high sensitivity and NPV, establishing it as a viable tool for opportunistic early CC screening in hospitals, particularly among older women. The combination of TS test with hrHPV test enhances both sensitivity and specificity, thereby minimizing unnecessary colposcopies. Further large-scale studies are required to validate its long-term effectiveness in low- and middle-income countries (LMICs).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A real-world multicenter study on opportunistic cervical cancer screening in hospital in China: comparison of TruScreen device, cytology, and HPV testing for detecting high-grade cervical lesions
- Date Crossref
- 04/02/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Chinese Academy of Medical Sciences & Peking Union Medical College pays non établi dans la noticeUniversité ou école supérieure
-
Peking Union Medical College Hospital Department of Obstetrics and Gynecology pays non établi dans la noticeÉtablissement de santé
-
Capital Medical University Beijing Chao-Yang Hospital pays non établi dans la noticeÉtablissement de santé
-
Fujian Provincial Hospital pays non établi dans la noticeÉtablissement de santé
-
Beijing Obstetrics and Gynecology Hospital pays non établi dans la noticeÉtablissement de santé
-
Peking University Department of Obstetrics and Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
Peking University Third Hospital pays non établi dans la noticeÉtablissement de santé
-
Sichuan Cancer Hospital pays non établi dans la noticeÉtablissement de santé
-
Central South University Department of Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
Xiangya Hospital Central South University pays non établi dans la noticeÉtablissement de santé
-
China Medical University Department of Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
The People's Hospital of Guangxi Zhuang Autonomous Region pays non établi dans la noticeÉtablissement de santé
Chinese Academy of Medical Sciences & Peking Union Medical College, Department of Obstetrics and Gynecology — Peking Union Medical College Hospital et Beijing Chao-Yang Hospital — Capital Medical University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.